- Home
- CNTA
as 05-09-2025 4:00pm EST
Centessa Pharmaceuticals PLC is a clinical-stage pharmaceutical company. The company's pipeline assets include: SerpinPC for Hemophilia A, B; LB101 for Solid Tumors; ORX750 for Narcolepsy Type 1 (NT1) and other sleep disorders; MGX292 Pulmonary Arterial Hypertension (PAH); and Undisclosed for Solid Tumors.
| Founded: | 2020 | Country: | United Kingdom |
| Employees: | N/A | City: | ALTRINCHAM, CHESHIRE |
| Market Cap: | 1.8B | IPO Year: | 2021 |
| Target Price: | $26.11 | AVG Volume (30 days): | 617.5K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 10 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.06 | EPS Growth: | N/A |
| 52 Week Low/High: | $7.75 - $19.09 | Next Earning Date: | 05-20-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Stock Insider Trading Activity of Centessa Pharmaceuticals plc (CNTA)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| HUSSAIN IQBAL J | CNTA | General Counsel | May 1 '25 | Sell | $14.00 | 311 | $4,354.00 | 105,386 | |
| HUSSAIN IQBAL J | CNTA | General Counsel | Apr 25 '25 | Sell | $14.00 | 5,689 | $79,658.01 | 105,386 | |
| Weinhoff Gregory M | CNTA | Chief Business Officer | Apr 25 '25 | Sell | $13.61 | 11,742 | $159,856.76 | 122,279 | |
| SAHA SAURABH | CNTA | Chief Executive Officer | Apr 21 '25 | Sell | $12.36 | 55,000 | $681,576.18 | 221,017 | |
| Weinhoff Gregory M | CNTA | Chief Business Officer | Mar 25 '25 | Sell | $16.34 | 10,000 | $163,386.00 | 122,279 | |
| SAHA SAURABH | CNTA | Chief Executive Officer | Mar 20 '25 | Sell | $16.69 | 55,000 | $918,060.00 | 221,017 | |
| HUSSAIN IQBAL J | CNTA | General Counsel | Mar 17 '25 | Sell | $16.45 | 6,000 | $98,697.00 | 105,386 | |
| CHAO DAVID M | CNTA | Chief Administrative Officer | Mar 17 '25 | Sell | $17.29 | 7,000 | $120,205.87 | 225,007 | |
| Weinhoff Gregory M | CNTA | Chief Business Officer | Feb 25 '25 | Sell | $15.25 | 11,494 | $175,269.71 | 122,279 | |
| SAHA SAURABH | CNTA | Chief Executive Officer | Feb 20 '25 | Sell | $16.23 | 55,000 | $876,087.94 | 221,017 |
Latest Centessa Pharmaceuticals plc News
CNTA Breaking Stock News: Dive into CNTA Ticker-Specific Updates for Smart Investing
MT Newswires
2 days ago
Chardan Initiates Centessa Pharmaceuticals at Buy With $30 Price Target
Insider Monkey
5 days ago
Is Centessa Pharmaceuticals plc (CNTA) the Best Small Cap Stock to Buy with the Biggest Upside Potential?
MT Newswires
17 days ago
Centessa Pharmaceuticals Insider Sold Shares Worth $681,576, According to a Recent SEC Filing
MT Newswires
a month ago
Piper Sandler Initiates Centessa Pharmaceuticals at Overweight With $38 Price Target
GlobeNewswire
2 months ago
Centessa Pharmaceuticals Reports Business Highlights and Financial Results for the Fourth Quarter and Full-Year 2024
GlobeNewswire
2 months ago
Centessa Pharmaceuticals Announces Poster Presentation of Phase 1 Clinical Data for ORX750, a novel orexin receptor 2 (OX2R) agonist, at the American Academy of Neurology (AAN) 2025 Annual Meeting
MT Newswires
3 months ago
Centessa Pharmaceuticals Insider Sold Shares Worth $588,944, According to a Recent SEC Filing
GlobeNewswire
3 months ago
Centessa Pharmaceuticals to Participate in Upcoming Investor Conferences
Compare CNTA vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "CNTA Centessa Pharmaceuticals plc - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.